-
公开(公告)号：US20230159592A1
公开(公告)日：2023-05-25
申请号：US17854379
申请日：2022-06-30
发明人： Harold B. Wood , Hubert B. Josien , Thomas Joseph Tucker , Angela Dawn Kerekes , Ling Tong , Abbas M. Walji , Anilkumar G. Nair , Fa-Xiang Ding , Elisabetta Bianchi , Danila Branca , Chengwei Wu , Yusheng Xiong , Sookhee Nicole HA , Jian Liu , Sobhana Babu Boga
摘要： Disclosed are compounds of Formula I, or a salt thereof:
where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.-
公开(公告)号：US20230303625A1
公开(公告)日：2023-09-28
申请号：US17935726
申请日：2022-09-27
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole HA , Hyewon Youm , Mark W. EMBREY , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. GILBERT , Aurash Shahripour , Yusheng Xiong
IPC分类号： C07K7/64
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
搜索结果
2 条记录 (耗时 0.015 秒)
